Lucentis contains human antibody fragments, known for their ability to prevent new blood vessel formation under the retina. Use this eye injection to treat retinal diseases including wet age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy with DME, and myopic choroidal neovascularization. Administer this eye drug to prevent leakage of blood and fluid under the retina.
LUCENTIS® English Alternative
OphthalmologyProduct: LUCENTIS® 0.23 mg English Alternative
Manufacturer: Novartis
Active Substance(s): Ranibizumab
Strength: 2.3mg
Pack Size: 1-0.23ml vial
Accessories: Package insert
$1,599.00
